Roth Capital Resumes Juniper Pharmaceuticals (JNP) at Buy

January 2, 2018 7:41 AM

Roth Capital resumes coverage on Juniper Pharmaceuticals (NASDAQ: JNP) with a Buy rating and a price target of $12.00.Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found